Tier 3 — preclinical
Sirtuin 6 activator UBCS039 ameliorates hepatic lipogenesis through liver X receptor deacetylation
International Immunopharmacology
2026
168(Pt 2):115878
Bibliography
- PubMed
- PMID 41265217
- Funding
- Supported by a National Research Foundation of Korea grant funded by the Korean Government (MSIT), 2022R1C1C1003563.
- Competing interests
- The authors declared no known competing financial interests or personal relationships that could have appeared to influence the work.
Study snapshot
| Design | Mechanistic pharmacology study integrating public human NAFLD transcriptomic data, hepatocyte experiments and mouse liver-steatosis models. |
|---|---|
| Model | Human transcriptomic datasets, cultured hepatocytes and mice. |
| Sample | Preclinical experiments and public human datasets; endpoint-specific sizes reported in the paper. |
| Intervention | UBCS039 SIRT6 activator. |
| Duration | Experiment-dependent. |
| Endpoints | LXR deacetylation/activity; SREBF1 and lipogenic gene expression; hepatocyte lipid accumulation; NF-kappaB signaling; mouse hepatic steatosis |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- SIRT6, Metabolism & Diabetes: Glucose, Liver, Kidney and Human EvidenceSIRT6 regulates glucose, HIF-1alpha, insulin sensitivity and liver lipid metabolism in preclinical research. See what human and activator studies actually support.Read analysis
- SIRT6 Activator Benefits: What the Evidence Actually ShowsSIRT6 activator benefits are strongest for DNA repair and other mechanistic pathways, with mouse evidence for longevity and metabolism. Human anti-aging benefits...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
